SCYNEXIS, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
SCYNEXIS, Inc. (SCYX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $400.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2023-03-31
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $400.00K.
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $400.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2022-12-31 | $400.00K 10-K · filed 2023-03-31 |
| 2021-12-31 | $400.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |